Eli Lilly (LLY) PT Raised to $884 at Guggenheim
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mailGet Alerts LLY Hot Sheet
Price: $1,417.99 --0%
Rating Summary:
31 Buy, 4 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Rating Summary:
31 Buy, 4 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Join SI Premium – FREE
Guggenheim analyst Seamus Fernandez raised the price target on Eli Lilly (NYSE: LLY) to $884.00 (from $855.00) while maintaining a Buy rating.
You May Also Be Interested In
- Lilly to present retatrutide and combo drug data at ACR 2026
- United Therapeutics Corp. (UTHR) PT Raised to $725 at RBC Capital
- Viridian Therapeutic (VRDN) PT Raised to $41 at RBC Capital
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
